Navigation Links
The ETICS Project, Led by CYTOO in Collaboration With Cellectis bioresearch and the CEA, to Receive Euro 7.6 Million in Funding From OSEO
Date:9/26/2011

PARIS, Sept. 26, 2011 /PRNewswire/ -- CYTOO, a company that specializes in cell-based assays (Grenoble, France), has joined up with Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (Alternext: ALCLS), and the CEA, the French Alternative Energies and Atomic Energy Commission, to develop new high-value cell-based assays for drug development and toxicology.

The project, named ETICS(1), will focus on the development of cell-based assays, which will be commercialized as kits, comprising cells genetically modified by Cellectis bioresearch and CYTOO's micropatterned supports. By controlling the expression, the architecture and the 2D and 3D environment of the cells, thus mimicking in vivo conditions of the tissue they derive from (liver, heart...), these assays will have much higher relevance to discover better and safer drugs.

OSEO, the French agency financing innovation, is providing euro 7.6 million in funding for the ETICS project for the next 5 years, including euro 4 million for CYTOO, euro 2.9 million for Cellectis bioresearch and euro 0.7 million for the CEA. This project could generate over euro 600 million for the consortium in ten years.

"The three partners of the ETICS project have complementary know-how and synergies in the key domains necessary for the success of such a project," said Francois Chatelain, Chairman and CEO of CYTOO.

"This funding will enable us to extend our product offering and to gain market share from our major North American competitors," stated Marc Le Bozec, Cellectis bioresearch CEO. "I would like to congratulate the ETICS partners and OSEO teams for the quality of work accomplished, which we believe will yield an important advancement in the development of new drugs."

About the "Industrial Strategic Innovation" Program from OSEO

The "Industrial Strategic Innovation" (ISI) program supports the emergence of
'/>"/>

SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Genetics Determine Optimal Drug Dose of Common Anticoagulant
4. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
5. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
7. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
10. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
11. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN DIEGO, July 31, 2014  ResMed Inc. (NYSE: ... and for the fiscal year ended June 30, 2014.  Revenue ... quarter ended June 30, 2013 (a 1 percent decrease on ... increase of 20 percent compared to the quarter ended June ... $0.61, an increase of 22 percent compared to the quarter ...
(Date:7/31/2014)... SAN FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... the second quarter ended June 30, 2014. ... were $301.4 million as compared to $309.1 million at March ... time for Nektar as we look forward to significant milestones ... W. Robin, President and Chief Executive Officer of Nektar. "The ...
(Date:7/31/2014)... 31, 2014  Decision Resources Group,s experts ... by the Affordable Care Act (ACA), which ... pharmaceutical therapies. The ACA altered how Managed ... regulations and expanded access via government-supported programs. ... exchanges—state-based marketplaces set up by states or ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... Inc. (ARKRAY) announced today that the GLUCOCARD® Vital and ... (DoD) Uniform Formulary.  The DoD Pharmacy and Therapeutic committee ... 01 Blood Glucose Meters as the first and second ... of service as noted by the Uniform Formulary Beneficiary ...
... Oct. 28, 2011 Pearl Therapeutics Inc. presented ... foundations of the Company,s cosuspension technology which uses ... via pressurized metered dose inhalers (MDIs). Two posters ... Association of Pharmaceutical Scientists annual meeting in Washington ...
Cached Medicine Technology:ARKRAY's GLUCOCARD® Vital and 01 Blood Glucose Meters are now on the Department of Defense Uniform Formulary. 2Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform 2Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform 3
(Date:8/1/2014)... On Monday, June 30th, the Quirk Healthcare ... San Francisco, CA. Now in its fourth year, the ... Square hotel. , “We are excited about returning to ... ACA compliance issues,” Quirk Healthcare Foundation Executive Director, Ben ... guidance with NextGen implementation and use, electronic records documentation ...
(Date:8/1/2014)... 2014 (HealthDay News) -- Patients with the progressive, deadly ... have a new weapon to battle the disease, the ... The agency approved a new treatment, an inhaled spray ... killer of Americans. COPD, which is often linked to ... and emphysema. Patients with COPD may experience ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Although many parents worry ... overlook a common choking hazard: food. Such was ... and cough after eating a handful of nuts. "At ... obvious if the coughing was related to his illness or ... a cold. A cashew had become lodged in his windpipe ...
(Date:8/1/2014)... The North America Endpoint Security Market ... in North America with analysis and forecast of revenue. ... billion in 2014 to $4.77 billion by 2019, at ... Browse through the TOC of the North America Endpoint ... in-depth analysis provided. It also provides a glimpse of ...
(Date:8/1/2014)... 01, 2014 Over the past ... from innovative technologies that have enabled cosmetic dentists ... tooth color. Moreover, the burgeoning elderly population has ... tooth ailments. Due to long-term use of medications, ... have demanded dental fillings, veneers and implants. As ...
Breaking Medicine News(10 mins):Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:FDA Approves New Treatment for People With COPD 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... has announced that people should reduce the salt intake to avoid ... be limited to 6 g per day//. FSA also stressed that ... in their food labels. ,Too much of salt is ... high blood pressure, which can lead to heart attacks. The amount ...
... better to insert drug-coated stents to keep the blood ... ,The study author Dr. Manel Sabate, a consultant ... said that the results of this study are noteworthy ... compared to non-diabetics after angioplasty. The complete report of ...
... team have found out the benefits of oral ZYVOX ... by bacterial infections. They compared data from 80 health ... of Intravenous Vancomycin. The results show that oral ... savings of money spent to health clinics compared to ...
... From arugula leaves that have a crunch and a peppery ... markets is finding its way into the most divine salad ... coloured bell peppers are becoming hot favourites for toss-it-up-your-way spreads. ... that greens offer a wave of flavours for every palate. ...
... common symptoms, due to which physicians often tend to get ... when the tongue or throat muscles // relax too much ... than 50 times an hour during sleep, causing snoring and ... The problem is twice as common in men, and it ...
... is important for fish food to be cooked the right way ... cooking preparation is as important as the amount of fat and ... the nutrition facts? Just one piece of batter-dipped fish has 170 ... by fried stuff, hushpuppies and coleslaw will probably give you 1,240 ...
Cached Medicine News:Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2Health News:Reversibility of symptoms of depression using CPAP in patients with obstructive sleep apnea 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: